Genzyme Corp. said today that it has begun shipping doses of its Fabrazyme drug from its new plant in Framingham.
The move follows an announcement in January that federal regulators had given Cambridge-based Genzyme the approval to begin producing Fabrazyme at the company’s new Framingham plant. With the Framingham plan coming on line, patients in the United States are now able to return to full dosing in March following a period in which they had to deal with a shortage.
Fabrazyme is a treatment for Fabry’s disease, a rare enzyme deficiency that causes waste to accumulate in the body.
Fabrazyme had been produced at Genzyme’s facility at Allston Landing in Boston. But problems at that facility caused a temporarily halt in production and a rationing of Fabrazyme. Those production issues have been addressed, and with the Framingham facility now shipping Fabrazyme, patients living outside the United States should be able to resume full doses later in the year, Genzyme said.
To read today’s press release from Genzyme, please click here.
Genzyme is now a unit of Sanofi SA. Last year, the French drug maker purchased Genzyme for $20.1 billion.
Chris Reidy can be reached at firstname.lastname@example.org.